Antifungal Therapy Guidelines for Pediatric Acute Leukemia Patients Infected with Candida and Aspergillus Species

An Analysis of Discrepancies between Published and Hospital-based Guidance

Ingrid Jacobson
University of Minnesota School of Public Health
Executive Summary

The most recent published antifungal guidelines for pediatric acute leukemia patients recommend treating *Candida* infections with echinocandins and treating *Aspergillus* infections with voriconazole, with liposomal amphotericin B as an acceptable alternative treatment for both. US hospital-based guidelines agree with the most recent published guidelines; however, international hospital-based guidelines do not.
Table of Contents

01. Issue Overview

02. Methods

03. Findings: Published and Hospital-based *Candida* Treatment Recommendations

06. Findings: Published and Hospital-based *Aspergillus* Treatment Recommendations

09. Conclusions

10. Further Discussion and Future Research Directions

11. Disclaimer and Note on Antifungal Prophylaxis

12. References

15. Acknowledgements
**Issue Overview**

*Candida* spp. and *Aspergillus* spp. are the leading causes of invasive fungal infection (IFI) in pediatric acute leukemia patients worldwide. They are a major cause of morbidity among these patients, with high mortality rates (10% to 50% for *Candida* infections and 25% to 80% for *Aspergillus* infections). Additionally, these infections are difficult to diagnose and cure.

Pediatric antifungal drug and dosage guidelines help providers combat these infections, but hospital-based guidelines may not always use the most up-to-date published data.

We compared published and hospital-based guidelines to determine any discrepancies between the most up-to-date guidelines on pediatric antifungal use for suspected and confirmed invasive fungal infections for children with leukemia and what is recommended in hospitals in the United States and internationally.
Methods

We reviewed 9 guidelines or consensus statements published by professional groups in the peer-reviewed literature, 5 international hospital-based guidelines, and 10 US hospital-based guidelines for recommendations applicable to pediatric acute leukemia patients.

We then compiled a summary of recommended antifungal drugs and dosages using 5 of the professional society guidelines published in the literature, 3 of the international guidelines, and 4 of the US guidelines.
Findings: Published Candida Treatment Recommendations

The current published guidelines recommend treating Candida infections initially with echinocandins. There are currently more data available on caspofungin and micafungin than there on anidulafungin, with guidelines giving caspofungin and micafungin a stronger recommendation. The strongest alternative recommendation is liposomal amphotericin B. Voriconazole (accompanied by therapeutic drug monitoring) and fluconazole are also acceptable alternatives. Standardized treatment durations are not specified, and clinicians are instructed to administer therapy until 2 weeks after the infection is cleared.

More complicated invasive Candida infections have their own specific recommendations based on the complication itself. Endocarditis can be treated with either echinocandins or amphotericin B, meningoencephalitis should be treated with liposomal amphotericin B (possibly in combination with flucytosine), and hepatosplenic candidiasis can be treated with either echinocandins or liposomal amphotericin B, followed by fluconazole.

Table 1: Candida Antifungal Dosage Recommendations

<table>
<thead>
<tr>
<th>YEAR OF PUBLICATION</th>
<th>CASPOFUNGIN*</th>
<th>MICAFUNGIN</th>
<th>LIPOSOMAL AMPHOTERICIN B</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>50 mg/m² daily</td>
<td>1-4 mg/kg/day</td>
<td>1-5 mg/kg/day</td>
</tr>
<tr>
<td>2019</td>
<td>50 mg/m² daily**</td>
<td>2-4 mg/kg/day***</td>
<td>3 mg/kg/day (IV)</td>
</tr>
<tr>
<td>2021</td>
<td>50 mg/m² daily**</td>
<td>2-4 mg/kg/day***</td>
<td>3 mg/kg/day (IV)</td>
</tr>
</tbody>
</table>

*Caspofungin is dosed based on surface area (mg/m²)
**Loading dose: 70 mg/m²
***If weight > 50 kg, then 100–200 mg/kday
Internationally, there is no clear agreement on the primary antifungal of choice. The NHS University Hospital in Bristol, England, recommends treating a probable systemic *Candida* infection with oral fluconazole.

NHS Greater Glasgow and Clyde in Scotland recommends treating a *Candida* infection with liposomal amphotericin B, and lists caspofungin as an acceptable alternative.

Children’s Health Queensland Hospital and Health Service in Australia recommends caspofungin or micafungin as first-line therapy, with voriconazole or liposomal amphotericin B as alternatives. If the patient has a complicated urinary tract infection, Children’s Health Queensland recommends fluconazole as the first-line drug. NHS Greater Glasgow and Clyde and Children’s Health Queensland agree that, for patients with a central nervous system infection, voriconazole is the recommended drug.

Findings: International Hospital-based Candida Treatment Recommendations
Findings: US Hospital-based Candida Treatment Recommendations

US hospitals tend to recommend micafungin as the primary antifungal of choice over caspofungin.

UC Davis (California), Children’s Minnesota, and C.S. Mott Children’s Hospital (Michigan) recommend micafungin as first-line therapy for Candida infections, while UCSF Benioff Children’s Hospital (California) recommends caspofungin.

C.S. Mott and UCSF Benioff list liposomal amphotericin B as an acceptable alternative, and UCSF Benioff also lists fluconazole and voriconazole as acceptable alternatives, depending on the specific Candida species identified.
Findings: Published Aspergillus Treatment Recommendations

The current published guidelines recommend treating Aspergillus infections with voriconazole, accompanied by therapeutic drug monitoring. Voriconazole can have toxic side effects, with kidney injury a particular concern, and monitoring the trough levels of this antifungal may optimize the therapy while minimizing the potential for toxicity.

Liposomal amphotericin B is an alternative recommendation.
Combination therapy is not recommended.

Table 2. Aspergillus Antifungal Dosage Recommendations

<table>
<thead>
<tr>
<th>YEAR OF PUBLICATION</th>
<th>VORICONAZOLE (2-12 YO OR 12-14 YO WEIGHING &lt; 50 KG)</th>
<th>VORICONAZOLE (15+ YO OR 12-14 YO WEIGHING &gt; 50 KG)</th>
<th>LIPOSOMAL AMPHOTERICIN B</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>4 mg/kg twice daily*</td>
<td>4 mg/kg twice daily*</td>
<td>1-5 mg/kg/day</td>
</tr>
<tr>
<td>2019</td>
<td>8 mg/kg twice daily (IV) 9 mg/kg twice daily (oral)</td>
<td>4 mg/kg twice daily (IV) 200 mg twice daily (oral)</td>
<td>3 mg/kg/day (IV)</td>
</tr>
<tr>
<td>2019</td>
<td>8 mg/kg twice daily (IV) 9 mg/kg twice daily (oral)</td>
<td>4 mg/kg twice daily (IV) 200 mg twice daily (oral)</td>
<td>3 mg/kg/day (IV)</td>
</tr>
<tr>
<td>2021</td>
<td>8 mg/kg twice daily (IV) 9 mg/kg twice daily (oral)</td>
<td>4 mg/kg twice daily (IV) 200 mg twice daily (oral)</td>
<td>3 mg/kg/day</td>
</tr>
<tr>
<td>2022</td>
<td>8 mg/kg twice daily (IV) 9 mg/kg twice daily (oral)</td>
<td>4 mg/kg twice daily (IV) 200 mg twice daily (oral)</td>
<td>--</td>
</tr>
</tbody>
</table>

*on day 1, 6 mg/kg twice daily
Findings: International Hospital-based Aspergillus Treatment Recommendations

Internationally, there is disagreement over whether voriconazole or liposomal amphotericin B is the preferred first-line drug for invasive *Aspergillus* infections. The NHS University Hospital in Bristol recommends treating an *Aspergillus* infection empirically with liposomal amphotericin B as a first-line drug. Voriconazole with therapeutic drug monitoring is the second-line therapeutic approach and should be combined with caspofungin until adequate blood levels of voriconazole are achieved, at which point caspofungin treatment can be halted.

NHS Greater Glasgow and Clyde recommends liposomal amphotericin B as the first-line drug, with fluconazole or voriconazole with therapeutic drug monitoring as acceptable alternatives. Posaconazole is the second-line drug, although posaconazole is not currently approved in children under 13 years of age.

Children’s Health Queensland Hospital and Health Service recommends voriconazole with therapeutic drug monitoring as the first-line approach, with liposomal amphotericin B as an acceptable alternative.
Findings: US Hospital-based Aspergillus Treatment Recommendations

In the United States, all hospitals investigated in this comparison recommend voriconazole as the preferred first-line drug. UCSF Benioff also lists liposomal amphotericin B as an acceptable alternative.
Conclusions

The most recent published data on the first-line therapy for invasive fungal infections in children with leukemia recommend that *Candida* infections be treated with an echinocandin—either caspofungin or micafungin—and that *Aspergillus* infections be treated with voriconazole accompanied by therapeutic drug monitoring. Liposomal amphotericin B is an acceptable alternative treatment for both types of infections but is not the first choice.

Internationally, only Children’s Health Queensland Hospital and Health Service in Australia follows these recommendations. This is likely because this facility is heavily involved in the academic research behind the most recent published data.

The other two international hospitals investigated in this comparison recommend fluconazole and liposomal amphotericin B for *Candida* infections and liposomal amphotericin B for *Aspergillus* infections, contrary to the most recent published data. This indicates a large discrepancy among first-line antifungal prescriptions internationally.
Further Discussion and Future Research Directions

Pediatric-specific data

A serious lack of pediatric data concerning antifungals and acute leukemia has led to the possibly inappropriate use of adult data to inform pediatric guidelines. Additional research is necessary to determine the optimal dosages and durations of antifungal therapies for immunocompromised pediatric patients.

Public availability of guidelines

Nationally, many US hospitals did not have publicly available antifungal guidelines. US hospitals should consider making their antifungal guidelines publicly available to increase data transparency and assist in future pediatric antifungal research.

Guideline concordance with published data

Two international hospitals based in Bristol (England) and Glasgow and Clyde (Scotland) have current antifungal guidelines that do not agree with the most recent published data. Additional comparisons should be done between UK hospital-based guidelines and the most recent published data to determine if this is a trend in this region.
Disclaimer

The information presented in this issue brief is intended to provide an understanding of the landscape of recommendations for treatment of suspected or confirmed invasive fungal infections in children with leukemia. It is not intended to provide clinical advice or guidance, and it does not include an analysis of studies or clinical experience that may offer greater insight into individual and nuanced prescribing decisions in these complex scenarios.

Note on antifungal prophylaxis

This comparison did not investigate current guidelines for antifungal prophylaxis. This comparison is solely about treatment recommendations for confirmed fungal infection (and probable/empirical treatment where indicated in the text).
References


Emergency department and outpatient specialty care clinical pathway for oncology patient presenting with fever. Children’s Hospital of Philadelphia. Revised May 2022 [Web page]


Initial management of fever (≥38.3 or 38.0 x 2) and neutropenia (ANC <500) in children. University of California, Davis. Approved October 2019 [Web page]


Management of fever in pediatric oncology and BMT patients. Infectious Diseases Management Program at University of California San Francisco. Modified July 2019 [Web page]


Neutropenic fever inpatient adult treatment (hematologic cancers including lymphoma and myeloma). MD Anderson Cancer Center. Approved June 2022 [Web page]
Pediatric empiric treatment recommendations for select infections. St. Louis Children’s Hospital. Revised July 2022 [Web page]

HemOnc BMT suspected infection (HOBSI) pathway v12.0. Seattle Children’s Hospital. Updated November 2022 [Web page]


Yeast infection (candidiasis). Cincinnati Children's Hospital. Updated November 2022 [Web page]

Acknowledgements

Special thanks to the following people who provided valuable work and perspective on the report.

The report was researched and written by Ingrid Jacobson in fulfillment of the University of Minnesota School of Public Health Applied Practice Experience (APEx).

Natalie Vestin, MPH, served as APEx preceptor.

Jim Wappes edited and proofread the report.

Contact

Center for Infectious Disease Research and Policy Antimicrobial Stewardship Project (CIDRAP-ASP)

University of Minnesota
Minneapolis, Minnesota, USA

cidrap.umn.edu/asp
asp-cid@umn.edu
Twitter: @CIDRAP_ASC